We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Toshiba Announces PET Distribution Agreement

By HospiMedica staff writers
Posted on 11 Nov 2003
Under the terms of a distribution agreement, Toshiba Medical Systems Corp. (Tokyo, Japan; www.toshiba.com) will distribute in Japan certain positron emission tomography (PET) products of CPS Innovations, the trade name for CTI Systems, Inc., a joint venture of CTI Molecular Imaging, Inc. (Knoxville, TN, USA) and Siemens Medical Solutions USA, Inc. (Malvern, PA, USA).

The PET systems to be distributed by Toshiba will feature the LSO FastPET technology of CPS and will be supported by Toshiba's customer service force. This technology allows for much faster scanning times than predecessor technologies and is well suited for clinical applications in Japan, because its physical characteristics maximize image quality at the lowest possible dose level.

"We will be able to provide our customers in Japan with the highest diagnostic performance by combining the CPS PET systems and our specialized applications technology cultivated with our SPECT technology,” said Kenichiro Katsumata, senior vice president, Toshiba Medical Systems Corp.





Related Links:
Toshiba Med. Systems
CTI
Siemens Med. Solutions USA
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Patient Preoperative Skin Preparation
BD ChloraPrep

Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more